InMed Pharmaceuticals

InMed Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of InMed Pharmaceuticals (INM) as of Nov 2, 2026 is 95.16 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 91.13 % — a change of 4.42% (higher).

FCF Conversion

95.16 %

YoY

4.42%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of InMed Pharmaceuticals is 2025 95.16 % . FCF Conversion Rate (FCF/EBITDA) of InMed Pharmaceuticals was 2024 91.13 % . It decreases by 4.42% higher compared to the previous year.

The InMed Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
55.44 USD
Jan 1, 2019
66.43 USD
Jan 1, 2020
82.89 USD
Jan 1, 2021
95.98 USD
Jan 1, 2022
83.98 USD
Jan 1, 2023
93.58 USD
Jan 1, 2024
91.13 USD
Jan 1, 2025
95.16 USD
The InMed Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
95.16 %+4.42%
91.13 %-2.62%
93.58 %+11.44%
83.98 %-12.50%
95.98 %+15.80%
82.89 %+24.77%
66.43 %+19.83%
55.44 %-20.16%
69.44 %+227.08%
21.23 %-54.56%
46.72 %-16.05%
55.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

InMed Pharmaceuticals Stock analysis

What does InMed Pharmaceuticals do? InMed Pharmaceuticals Inc is a biopharmaceutical company based in Vancouver, Canada, listed on the stock exchange in June 2001. The firm operates through two main segments: InMed Pharmaceuticals and BayMedica. The InMed segment focuses on the research and development of prescription-based cannabinoid products, specifically targeting diseases with high unmet medical needs. Key candidates include INM-755, a topical skin cream for Epidermolysis Bullosa, and INM-088 for glaucoma treatment. The BayMedica segment develops proprietary manufacturing technologies to produce rare cannabinoids for the health and wellness industry. The company leverages its expertise in rare cannabinoids and analogs to address significant therapeutic gaps. InMed Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InMed Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of InMed Pharmaceuticals is 95.16 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of InMed Pharmaceuticals changed from 91.13 % to 95.16 %, representing a 4.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) InMed Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s InMed Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — InMed Pharmaceuticals

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — InMed Pharmaceuticals